Brief: Senti Bio Announces New Strategic Collaboration With Celest Therapeutics For Clinical Development Of Senti-301A In China

Senti Biosciences Holdings

06/11/2023 21:53

Nov 6 (Reuters) - Senti Biosciences Inc  SNTI.O :
    * SENTI BIO ANNOUNCES NEW STRATEGIC COLLABORATION WITH
CELEST
THERAPEUTICS FOR CLINICAL DEVELOPMENT OF SENTI-301A IN CHINA
    * SENTI BIOSCIENCES INC - FIRST PATIENT EXPECTED TO BE
ENROLLED IN
CHINA IN 1H 2024
    * SENTI BIOSCIENCES INC - CELEST TO LEAD CLINICAL
DEVELOPMENT WITH
TECHNICAL SUPPORT FROM SENTI BIO
    * SENTI BIOSCIENCES INC - SENTI BIO ELIGIBLE TO RECEIVE UP
TO $156
MILLION IN MILESTONES AND ROYALTIES
    * SENTI BIOSCIENCES INC - OTHER TERMS OF TRANSACTION WERE
NOT
DISCLOSED

Source text for Eikon:  ID:nGNX8ZrqSv 
Further company coverage:  SNTI.O 

 ((Reuters.Briefs@thomsonreuters.com))